Patient Groups Urge Congress To Support Biosimilars

Law360, New York (September 24, 2009, 6:14 PM EDT) -- A coalition of 27 patient advocacy groups is urging U.S. lawmakers working on massive health care reform to include bipartisan amendments creating a regulatory pathway for generic versions of biologic drugs.

In a letter to congressional leaders last week, Washington-based Colon Cancer Alliance and several other organizations said they supported amendments passed in U.S. House of Representatives and Senate committees to add a biosimilars provision to their health care proposals.

“In the face of the larger unresolved questions relating to the broader health care reform package,...
To view the full article, register now.